MANNKIND CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
MANNKIND CORP (MNKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $970000.00 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-02-23
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-09-30 was $1.06, a 92.73% increase year-over-year.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-03-31 was $1.86.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-09-30 was $0.55.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-06-30 was $0.63.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $970000.00, a 26.52% decline from fiscal 2019.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $1320000.00, a 87417118.54% increase from fiscal 2018.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $1.51, a 26.89% increase from fiscal 2017.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $1.19, a 60.98% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $970000.00 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $1320000.00 10-K · filed 2021-02-25 | $1.32 10-K · filed 2020-02-25 | |||
| 2018-12-31 | $1.51 10-K · filed 2020-02-25 | ||||
| 2017-12-31 | $1.19 10-K · filed 2019-02-26 | ||||
| 2017-09-30 | $1.06 10-Q · filed 2017-11-07 | ||||
| 2017-06-30 | $0.93 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $1.86 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | $3.05 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $0.55 10-Q · filed 2016-11-09 | ||||
| 2016-06-30 | $0.63 10-Q · filed 2016-11-09 | $0.74 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | $12.80 10-K · filed 2018-02-27 | $2.56 10-K · filed 2016-03-15 | |||
| 2014-12-31 | $23.80 10-K · filed 2017-03-16 | $4.76 10-K · filed 2015-03-02 | |||
| 2013-12-31 | $3.26 10-K · filed 2016-03-15 | ||||
| 2012-12-31 | $0.99 10-K · filed 2015-03-02 | ||||
| 2012-06-30 | $1.12 10-Q · filed 2012-08-09 | ||||
| 2011-12-31 | $2.04 10-K · filed 2014-03-03 | ||||
| 2010-12-31 | $4.06 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |